Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1079-1084

  Kobayashi, Yujin ^a   Miura, Katsuhiro ^a   Hojo, Atsuko ^a   Hatta, Yoshihiro ^a   Tanaka, Toshitake ^a   Kurita, Daisuke ^a   Iriyama, Noriyoshi ^a   Kobayashi, Sumiko ^a   Takeuchi, Jin ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Charlson Comorbidity Index; Comorbidities; Diffuse large B cell lymphoma; Elderly patients; Prognostic factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER STAGING; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HEALTH STATUS; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; JAPAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 79959750248     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0973-x     Document Type: Article

References (18)

1. Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14(1):1-16
2. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373-383 (Pubitemid 17055592)
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235-242. doi:10.1056/NEJMoa011795 (Pubitemid 34438862)
4. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y (1988) Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24(9-10):533-538 (Pubitemid 19052765)
5. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117-4126. doi:10.1200/JCO.2005.09.131 (Pubitemid 46211317)
6. Gridelli C (2008) Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol 26(1):13-15. doi:10.1200/JCO.2007.14.1820
7. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897-904. doi:10.1007/s00277-010-0956-7
8. Kim YJ, Kim JH, Park MS, Lee KW, Kim KI, Bang SM, Lee JS, Kim CH (2010) Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy. J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0945-1
9. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98(12):2651-2656. doi:10.1002/cncr.11846 (Pubitemid 37509529)
10. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 22(21):4302-4311. doi:10.1200/JCO.2004.03.213 (Pubitemid 41185151)
11. Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87(5):429-430. doi:10.1007/s00277-008-0447-2
12. Project-TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329(14): 987-994. doi:10.1056/NEJM199309303291402
13. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857-1861. doi:10.1182/blood-2006-08-038257 (Pubitemid 46348180)
14. Thieblemont C, Coiffier B (2007) Lymphoma in older patients. J Clin Oncol 25(14):1916-1923. doi:10.1200/JCO.2006.10.5957 (Pubitemid 46854426)
15. Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, Espinouse D, Coiffier B (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774-779. doi:10.1093/annonc/mdm563
16. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM (1998) CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16(1):27-34 (Pubitemid 28041575)
17. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115(19):4547-4553. doi:10.1002/cncr.24490
18. Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U (2010) Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0933-5